Navigation Links
Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
Date:11/5/2010

on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.Halozyme ContactRobert H. UhlSenior Director, Investor Relations(858) 704-8264ruhl@halozyme.comHalozyme Therapeutics, Inc.Condensed Consolidated Statements of OperationsThree Months EndedNine Months EndedSeptember 30, September 30,2010200920102009(unaudited)(unaudited)(unaudited)(unaudited)REVENUES:Product sales

$
98,100$
411,109$
95,440$
9,267Revenues under collaborative agreements

3,298,4072,617,7769,356,1516,558,145Total revenues

3,396,5073,028,88510,051,5917,227,412OPERATING EXPENSES:Cost of product sales

7,214102,63896,413151,939Research and development

12,448,86513,162,74835,840,47541,763,972Selling, general and administrative

3,374,0693,703,09910,488,56811,093,563Total operating expenses

15,830,14816,968,48546,425,45653,009,474OPERATING LOSS

(12,433,641)(13,939,600)(36,373,865)(45,782,062)Interest and other income, net

24,06529,31825,88986,391NET LOSS

$ (12,409,576)$ (13,910,282)$ (36,347,976)$ (45,695,671)Basic and diluted net loss per share

$
(0.13)$
(0.16)$
(0.39)$
(0.54)Shares used in computing basic and dilutednet loss per share

93,626,89389,570,54092,342,66585,086,456Halozyme Therapeutics, Inc.Condensed Consolidated Balance SheetsSeptember 30,December 31,20102009(unaudited)ASSETSCurrent assets:Cash and cash equivalents

$
89,840,588$   67,464,506Accounts receivable

2,622,0764,243,909Inventory

1,076,5801,159,551Prepaid expenses and other assets

4,891,5561,573,777Total current assets

98,430,80074,441,743Property and equipment, net

1,960,9352,708,016Total Assets

$   100,391,735$   77,149,759LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable

$
,828,069$
2,820,491Accrued expenses

5,052,7236,083,854Deferred revenue

4,900
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
2. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
3. Halozyme Therapeutics to Present at Upcoming Investor Conferences
4. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
5. Halozyme Therapeutics to Host Research Day for Investors and Analysts
6. Halozyme Therapeutics to Present at Upcoming Investor Conferences
7. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
8. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
9. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
10. Halozyme Receives $5.5 Million Payment From Baxter
11. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 ­ RedBrick Health ... behavior change technology, today announces that EmblemHealth , ... and wellness company, is now providing the RedBrick Compass ... coaching program, to all of its members. EmblemHealth is ...
(Date:1/15/2014)... NY (PRWEB) January 15, 2014 The Microcompetition ... a major disease. One of these latent viruses is the ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic inflammatory ... theory, a study found that RA patients have high concentrations ...
(Date:1/15/2014)... 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today ... R-Pharm, a leading Russian pharmaceutical company, to develop and ... Russian Federation , Turkey ... is a novel antibiotic for the treatment of bacterial ...
(Date:1/14/2014)... As pet owners drew up their lists of New Year,s ... better care of my furry companion." Nowadays there are pet salons, ... cases to take the little canine or feline darlings along wherever ... buy some pricey toys at the pet store. But anyone who ...
Breaking Biology Technology:EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2
... Clinton will,participate as one of the main speakers at the ... in Sao Paulo, Brazil. The event is organized by the,Brazilian ... gatherings focused on biofuels in the world. , ... a second term,in six decades. After leaving the White House, ...
... - Aegera Therapeutics is pleased to announce the ... for AEG33773, a novel, orally bio-available small molecule ... neuropathy. , The Phase 2a study, entitled A ... and Efficacy of AEG33773 versus Placebo in Patients ...
... announced successful,completion of the single-day oral dosing part ... patients with its new anti-cancer drug AXL1717,an,insulin-like growth ... the closely related insulin receptor. The study is ... The results showed that a single-day,dosing of AXL1717 ...
Cached Biology Technology:President Bill Clinton to Speak at the Ethanol Summit in Brazil 2Aegera Initiates Phase 2 Clinical Trial Of AEG33773 - A Small Molecule Targeting Neuropathic Pain 2Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB 2
(Date:4/18/2014)... crystallography and nuclear magnetic resonance imaging (NMR) to gain ... such efforts have long been hampered by the fact ... and often in ordered and crystalized form to be ... into the structure of most molecules. , Harvard researchers, ... of the past. , A team of scientists, ...
(Date:4/18/2014)... the past 20 years, researchers have published soil organic ... have suggested that soil organic carbon can be sequestered ... to no-till systems. However, there is a growing body ... and soybean rotations without cover crops, small grains, and ... at the published rates. , "Some studies have shown ...
(Date:4/18/2014)... Durham, NC Seeds that sprout as soon as they,re ... plants need to be more careful. In the wild, a ... rainy day would risk disaster. More than just an insurance ... out that seed dormancy has long-term advantages too: Plants ... give rise to more species, finds in a team of ...
Breaking Biology News(10 mins):MRI, on a molecular scale 2MRI, on a molecular scale 3Researchers question published no-till soil organic carbon sequestration rates 2Researchers question published no-till soil organic carbon sequestration rates 3Researchers question published no-till soil organic carbon sequestration rates 4Plants with dormant seeds give rise to more species 2
... may aid the quest for accurate, low-cost genomic sequencing, according ... by Stuart Lindsay and his collaborators at the Biodesign Institute ... an electron, can cross a barrier, when, according to classical ... Unraveling the DNA sequences of the human genome a ...
... N.J., March 4 BIO-key International, Inc. (OTC Bulletin ... finger-based biometric identification solutions, today announced that on or ... United States District Court for the Southern District of ... two of the Company,s investors, Longview Special Finance, Inc. ...
... Detects Faces in Motion, Matches with Watch-list ... Lithuania, March 9 Neurotechnology, a provider ... the availability of VeriLook Surveillance SDK, a ... using live video streams from high-resolution digital ...
Cached Biology News:Covering the bases: Quantum effect may hold promise for low-cost DNA sequencing, sensor applications 2Covering the bases: Quantum effect may hold promise for low-cost DNA sequencing, sensor applications 3Covering the bases: Quantum effect may hold promise for low-cost DNA sequencing, sensor applications 4BIO-key to Respond in Court to a Lawsuit Filed by Two Investors 2BIO-key to Respond in Court to a Lawsuit Filed by Two Investors 3VeriLook Surveillance SDK Provides Real-Time Face Identification Using Video Surveillance Cameras 2VeriLook Surveillance SDK Provides Real-Time Face Identification Using Video Surveillance Cameras 3
Homo sapiens olfactomedin 1, transcript variant 3...
RABBIT ANTI QUINOLINIC ACID...
Coverslips for Microarrays, 1. *Category: MICROARRAY ACCESSORIES....
Agarase cleaves agarose to neoagaro-oligosaccharides, and is used for,quantitative, gentle recovery of DNA from low melting point agarose....
Biology Products: